EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Dual ON/OFF-switch chimeric antigen receptor controlled by two clinically approved drugs

Greta Maria Paola Giordano Attianese iD, Sailan Shui, Elisabetta Cribioli, Melanie Triboulet, Leo Scheller, Morteza Hafezi, Patrick Reichenbach, Pablo Gainza, Sandrine Georgeon, Bruno E Correia iD, Melita Irving iD

Proceedings of the National Academy of Sciences · 2024

DOI: 10.1073/pnas.2405085121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Greta Maria Paola Giordano Attianese und 10 weiteren Autor:innen. Beteiligte Einrichtung: Ludwig Institute for Cancer Research Lausanne, Department of Oncology, University of Lausanne and Lausanne University Hospital, Lausanne 1011, Switze…. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Sulfonamides, T-Lymphocytes, Bridged Bicyclo Compounds, Heterocyclic. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fondation ISREC (ISREC Stiftung), EC | ERC | HORIZON EUROPE European Research Council (ERC), Prostate Cancer Foundation (PCF).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The ability to remotely control the activity of chimeric antigen receptors (CARs) with small molecules can improve the safety and efficacy of gene-modified T cells. Split ON- or OFF-switch CARs involve the dissociation of tumor–antigen binding from T cell activation (i.e., CD3ζ) on the receptor (R-) and signaling (S-) chains, respectively, that either associate or are disrupted in the presence of a small molecule. Here, we have developed an inducible (i)ON-CAR comprising the anti-apoptotic B cell lymphoma protein 2 protein in the ectodomain of both chains which associate in the presence of venetoclax. We showed that inducible ON (iON)-CAR T cells respond to target tumors cells in the presence of venetoclax or the BH3 mimetic navitoclax in a dose-dependent manner, while there is no impact of the drugs on equivalent second generation-CAR T cells. Within 48 h of venetoclax withdrawal, iON-CAR T cells lose the ability to respond to target tumor cells in vitro as evaluated by Interferon-gamma (IFNγ) production, and they are reliant upon the presence of venetoclax for in vivo activity. Finally, by fusing a degron sequence to the endodomain of the iON-CAR S-chain we generated an all-in-one ON/OFF-switch CAR, the iONØ-CAR, down-regulated by lenalidomide within 4 to 6 for functionally inactive T cells (no IFNγ production) within 24 h. We propose that our remote-control CAR designs can reduce toxicity in the clinic. Moreover, the periodic rest of iON and iONØ-CAR T cells may alleviate exhaustion and hence augment persistence and long-term tumor control in patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenSulfonamidesT-LymphocytesBridged Bicyclo Compounds, HeterocyclicHumansAnimalsMiceCell Line, TumorAntineoplastic AgentsImmunotherapy, AdoptiveProto-Oncogene Proteins c-bcl-2Xenograft Model Antitumor AssaysReceptors, Antigen, T-CellLymphocyte ActivationInterferon-gammaAniline Compounds

Stichwörter der Autor:innen

T cellcancerchimeric antigen receptorsynthetic biology

Substanzen

Receptors, Chimeric AntigenSulfonamidesvenetoclaxBridged Bicyclo Compounds, HeterocyclicAntineoplastic AgentsnavitoclaxProto-Oncogene Proteins c-bcl-2Receptors, Antigen, T-CellInterferon-gammaAniline Compounds

Autor:innen und Institutionen

  • Ludwig Institute for Cancer Research Lausanne, Department of Oncology, University of Lausanne and Lausanne University Hospital, Lausanne 1011, Switzerland.
  • Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne 1011, Switzerland.
  • Swiss Institute of Bioinformatics, Lausanne 1011, Switzerland.

ORCID-Profile: Greta Maria Paola Giordano Attianese, Bruno E Correia, Melita Irving

Förderung

  • Fondation ISREC (ISREC Stiftung)
  • EC | ERC | HORIZON EUROPE European Research Council (ERC)
  • Prostate Cancer Foundation (PCF)

Zitieren

APA

Giordano Attianese, G. M. P., Shui, S., Cribioli, E., Triboulet, M., Scheller, L., Hafezi, M., Reichenbach, P., Gainza, P., Georgeon, S., Correia, B. E., & Irving, M. (2024). Dual ON/OFF-switch chimeric antigen receptor controlled by two clinically approved drugs. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2405085121

Vancouver

Giordano Attianese GMP, Shui S, Cribioli E, Triboulet M, Scheller L, Hafezi M, et al. Dual ON/OFF-switch chimeric antigen receptor controlled by two clinically approved drugs. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2405085121

BibTeX
@article{GiordanoAttianese2024,
  author = {Giordano Attianese, Greta Maria Paola and Shui, Sailan and Cribioli, Elisabetta and Triboulet, Melanie and Scheller, Leo and Hafezi, Morteza and Reichenbach, Patrick and Gainza, Pablo and Georgeon, Sandrine and Correia, Bruno E and Irving, Melita},
  title = {Dual ON/OFF-switch chimeric antigen receptor controlled by two clinically approved drugs},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2024},
  doi = {10.1073/pnas.2405085121}
}
Kostenlos starten →